ZHONGHENG GROUP(SH:600252) Shang Hai Zheng Quan Bao·2025-11-27 19:26Core Viewpoint - The announcement highlights that Chongqing Laimei Pharmaceutical Co., Ltd., a subsidiary of Guangxi Wuzhou Zhongheng Group Co., Ltd., has received approval for a supplementary application for the injectable drug Aztreonam, which is expected to enhance its market competitiveness and future expansion opportunities [1][3]. Group 1: Drug Information - Aztreonam is indicated for the treatment of infections caused by sensitive Gram-negative bacteria, including urinary tract infections, lower respiratory tract infections, sepsis, skin and skin structure infections, intra-abdominal infections, and gynecological infections [1]. - The drug was developed by the French company Bristol-Myers Squibb and was first launched in France in 1983, followed by Italy in 1984, and subsequently in other European and American countries, with its introduction to China occurring in 1997 [1]. Group 2: Market Data - According to MoShang data, the sales revenue of Aztreonam in Chinese hospitals for the years 2023 to the first half of 2025 is projected to be 259 million yuan, 220 million yuan, and 40 million yuan, respectively [2]. - As of the date of the announcement, Laimei Pharmaceutical has invested a total of 6.3781 million yuan in the research and development of Aztreonam (unaudited data) [2]. Group 3: Impact on the Company - The approval of the supplementary application for Aztreonam is expected to improve the product's market competitiveness and facilitate future market expansion for the company [3]. - The pharmaceutical production and sales are subject to uncertainties due to factors such as changes in national policies, bidding procurement, and market environment fluctuations [3].